Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $75.35, for a total value of $1,507,000.00. Following the sale, the chief executive officer owned 733,719 shares in the company, valued at $55,285,726.65. This trade represents a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Helen Torley also recently made the following trade(s):
- On Friday, October 3rd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $69.03, for a total value of $1,380,600.00.
- On Wednesday, September 3rd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $74.44, for a total value of $1,488,800.00.
- On Tuesday, August 12th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $63.51, for a total value of $1,270,200.00.
- On Wednesday, July 9th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $56.43, for a total value of $1,128,600.00.
Halozyme Therapeutics Price Performance
Shares of NASDAQ HALO opened at $68.98 on Monday. The company has a debt-to-equity ratio of 4.54, a quick ratio of 7.01 and a current ratio of 8.36. The firm has a fifty day moving average of $70.45 and a 200 day moving average of $61.93. The firm has a market cap of $8.07 billion, a PE ratio of 15.78, a PEG ratio of 0.37 and a beta of 1.16. Halozyme Therapeutics, Inc. has a one year low of $42.01 and a one year high of $79.50.
Institutional Trading of Halozyme Therapeutics
Several hedge funds have recently added to or reduced their stakes in HALO. Wealth Preservation Advisors LLC acquired a new stake in shares of Halozyme Therapeutics in the 1st quarter valued at $32,000. Newbridge Financial Services Group Inc. acquired a new stake in shares of Halozyme Therapeutics in the 2nd quarter valued at about $32,000. SVB Wealth LLC acquired a new stake in shares of Halozyme Therapeutics in the first quarter valued at approximately $33,000. Bessemer Group Inc. grew its position in shares of Halozyme Therapeutics by 62.9% during the first quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 207 shares during the last quarter. Finally, Employees Retirement System of Texas acquired a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at $34,000. Institutional investors and hedge funds own 97.79% of the company’s stock.
Analyst Ratings Changes
Several equities analysts have recently weighed in on HALO shares. JPMorgan Chase & Co. raised their target price on Halozyme Therapeutics from $60.00 to $63.00 and gave the company a “neutral” rating in a research report on Thursday, August 7th. Wall Street Zen lowered Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, September 5th. Benchmark upped their target price on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a report on Wednesday, September 24th. The Goldman Sachs Group started coverage on shares of Halozyme Therapeutics in a research report on Thursday, July 10th. They issued a “neutral” rating and a $55.00 target price for the company. Finally, Morgan Stanley boosted their price target on shares of Halozyme Therapeutics from $75.00 to $80.00 and gave the stock an “overweight” rating in a research report on Monday, August 18th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $70.44.
View Our Latest Analysis on Halozyme Therapeutics
About Halozyme Therapeutics
Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
Featured Articles
- Five stocks we like better than Halozyme Therapeutics
- 3 Fintech Stocks With Good 2021 Prospects
- 3 Defense Stocks Surging as Ukraine Tensions Deepen
- Best Stocks Under $5.00
- Starbucks Stock Slumps; This Competitor Shows Strength
- How to Invest in the Best Canadian StocksĀ
- The Trade Desk: 2 Signs of a Comeback, 1 Risk Ahead
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.